Cargando…

MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis

Introduction: Thyroid stimulating hormone receptor autoantibodies (TRAb) are a diagnostic hallmark of Graves' disease (GD) and their clinical performance have been extensively reported in the medical literature. One of the three subtypes of TRAb is stimulating (S-TRAb), which leads to unregulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Bernardo, Cunha, Nuno, G. Martins, Raquel, Couto, Joana, Santos, Jacinta, Martins, Teresa, Soares, Rui, Valido, Frederico, Rodrigues, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551079/
http://dx.doi.org/10.1210/js.2019-MON-593
_version_ 1783424329903505408
author Marques, Bernardo
Cunha, Nuno
G. Martins, Raquel
Couto, Joana
Santos, Jacinta
Martins, Teresa
Soares, Rui
Valido, Frederico
Rodrigues, Fernando
author_facet Marques, Bernardo
Cunha, Nuno
G. Martins, Raquel
Couto, Joana
Santos, Jacinta
Martins, Teresa
Soares, Rui
Valido, Frederico
Rodrigues, Fernando
author_sort Marques, Bernardo
collection PubMed
description Introduction: Thyroid stimulating hormone receptor autoantibodies (TRAb) are a diagnostic hallmark of Graves' disease (GD) and their clinical performance have been extensively reported in the medical literature. One of the three subtypes of TRAb is stimulating (S-TRAb), which leads to unregulated thyroid hormone production by activating the TSH receptor on thyroid follicular cells. The aim of our study was to assess the clinical utility and accuracy of the immunoassay Siemens/Immulite TSI, that supposedly measures only S-TRAb and compare it with Roche/Cobas method which measures total TRAb, in the diagnosis of GD. Methods: We performed a prospective study, evaluating serum samples of 107 patients, between January and September of 2018: 36 with untreated GD (group 1) and 76 control subjects [group 2 - 40 with euthyroid multinodular goiter (EMNG), 24 with autoimmune thyroiditis (AIT) and 12 with toxic multinodular goiter (TMNG)]. GD was diagnosed according to the American Thyroid Association guidelines. Statistical analysis was performed using independent samples t-test. Results: Median value of TRAb and S-TRAb in group 1 patients was 13.3 (cut-off <1.7 UI/L) and 7.3 (cut-off <0.55 UI/L), respectively, versus 0.4 and 0.12 in group 2, respectively. In group 2, patients with TMNG had higher TRAb levels than patients with MNG and AIT (0.96 versus 0.48 and 0.49, respectively; p=0.011), but similar levels of TSI (0.14, 0.16 and 0.1, respectively; p=0.246).By receiver operating characteristics curve analysis, we obtained a TRAb value of 1.75 UI/L (sensitivity 97.8%; specificity 97.4%) and S-TRAb value of 0.75 UI/L (sensitivity 100%; specificity 98.7%) as the best cut-off values to diagnose GD. S-TRAb levels were positive in all GD patients and negative in all but one control (sensitivity 100%; specificity 98.7%), whereas TRAb were positive in all but one patient with GD and negative in all but two controls (sensitivity 96.8%; specificity 98.1%). Discussion:There are very few studies regarding the diagnostic utility and accuracy of S-TRAb in GD diagnosis. It has a very similar diagnostic accuracy compared to TRAb, but it could be useful in particular cases, as it has a slightly higher sensitivity and specificity and can accurately detect very low values of analyte.
format Online
Article
Text
id pubmed-6551079
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65510792019-06-13 MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis Marques, Bernardo Cunha, Nuno G. Martins, Raquel Couto, Joana Santos, Jacinta Martins, Teresa Soares, Rui Valido, Frederico Rodrigues, Fernando J Endocr Soc Thyroid Introduction: Thyroid stimulating hormone receptor autoantibodies (TRAb) are a diagnostic hallmark of Graves' disease (GD) and their clinical performance have been extensively reported in the medical literature. One of the three subtypes of TRAb is stimulating (S-TRAb), which leads to unregulated thyroid hormone production by activating the TSH receptor on thyroid follicular cells. The aim of our study was to assess the clinical utility and accuracy of the immunoassay Siemens/Immulite TSI, that supposedly measures only S-TRAb and compare it with Roche/Cobas method which measures total TRAb, in the diagnosis of GD. Methods: We performed a prospective study, evaluating serum samples of 107 patients, between January and September of 2018: 36 with untreated GD (group 1) and 76 control subjects [group 2 - 40 with euthyroid multinodular goiter (EMNG), 24 with autoimmune thyroiditis (AIT) and 12 with toxic multinodular goiter (TMNG)]. GD was diagnosed according to the American Thyroid Association guidelines. Statistical analysis was performed using independent samples t-test. Results: Median value of TRAb and S-TRAb in group 1 patients was 13.3 (cut-off <1.7 UI/L) and 7.3 (cut-off <0.55 UI/L), respectively, versus 0.4 and 0.12 in group 2, respectively. In group 2, patients with TMNG had higher TRAb levels than patients with MNG and AIT (0.96 versus 0.48 and 0.49, respectively; p=0.011), but similar levels of TSI (0.14, 0.16 and 0.1, respectively; p=0.246).By receiver operating characteristics curve analysis, we obtained a TRAb value of 1.75 UI/L (sensitivity 97.8%; specificity 97.4%) and S-TRAb value of 0.75 UI/L (sensitivity 100%; specificity 98.7%) as the best cut-off values to diagnose GD. S-TRAb levels were positive in all GD patients and negative in all but one control (sensitivity 100%; specificity 98.7%), whereas TRAb were positive in all but one patient with GD and negative in all but two controls (sensitivity 96.8%; specificity 98.1%). Discussion:There are very few studies regarding the diagnostic utility and accuracy of S-TRAb in GD diagnosis. It has a very similar diagnostic accuracy compared to TRAb, but it could be useful in particular cases, as it has a slightly higher sensitivity and specificity and can accurately detect very low values of analyte. Endocrine Society 2019-04-30 /pmc/articles/PMC6551079/ http://dx.doi.org/10.1210/js.2019-MON-593 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Thyroid
Marques, Bernardo
Cunha, Nuno
G. Martins, Raquel
Couto, Joana
Santos, Jacinta
Martins, Teresa
Soares, Rui
Valido, Frederico
Rodrigues, Fernando
MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
title MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
title_full MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
title_fullStr MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
title_full_unstemmed MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
title_short MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
title_sort mon-593 thyrotropin receptor stimulating immunoglobulin: clinical utility in graves' disease diagnosis
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551079/
http://dx.doi.org/10.1210/js.2019-MON-593
work_keys_str_mv AT marquesbernardo mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT cunhanuno mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT gmartinsraquel mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT coutojoana mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT santosjacinta mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT martinsteresa mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT soaresrui mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT validofrederico mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis
AT rodriguesfernando mon593thyrotropinreceptorstimulatingimmunoglobulinclinicalutilityingravesdiseasediagnosis